The present invention relates to novel crystalline forms of Vacquinol-1, in particular novel crystalline forms of (R)-(2-(4-chlorophenyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one such crystalline form, therapeutic or prophylactic use of such crystalline forms and compositions and methods of preparing such crystalline forms.
